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The cyclic decapeptide, polymyxin B (PMXB), was 
found to  inhibit hypoglycemia in mice receiving exog- 
enous  insulin  (Amir, S., and  Shechter, Y. (1985) Eur. 
J. Pharmacol. 110, 283-285). In  this  study,  we  have 
extended this observation to rats. Insulin-dependent 
hypoglycemia in  rats is efficiently blocked at a 12:l 
molar ratio of PMXB to insulin.  This  effect is highly 
specific, as it could not be mimicked by a variety of 
antibiotics or positively charged  substances. Chemical 
modifications of PMXB have  revealed  that  the  ring 
structure,  rather  than  the  tail  structure, is important 
for  anti-insulin-like  activity. Colistin A, which differs 
from PMXB by one  conservative  amino  acid  substitu- 
tion in the  ring  structure, is devoid of this  activity. 
Polymyxin  B does not interact  with insulin,  nor does 
it  alter  the  rate of insulin  absorption  and/or  degrada- 
tion, or  the  ability of insulin  to  bind  to  target tissues. 
This  peptide  inhibits hypoglycemia by  blocking  insu- 
lin-dependent  activation of the hexose transport mech- 
anism, as deduced by in vitro studies. The effect of 
insulin  in  stimulating hexose uptake  (and subsequent 
glucose metabolism) in  both  isolated muscle tissue  and 
adipocytes is blocked with little or no effect on the 
basal  activities of these processes. Colistin A has no 
significant  inhibiting  effect.  Other  insulin-dependent 
activities, such as inhibition of lipolysis in  adipocytes 
or  synthesis of  DNA in muscle cells, are not  inhibited. 
It is concluded that PMXB inhibits, in a highly  specific 
manner, the action of insulin in stimulating hexose 
transport  and subsequent glucose metabolism, both in 
vitro and  in  the whole animal model. 
In  the  last decade,  impressive achievements have been made 
with  respect  to  the  structure, basic properties,  and behavior 
of the  insulin  receptor (reviewed Refs. 1 to  3).  In  spite of this, 
the mechanism(s) of insulin action, in particular the post- 
binding events involved in hormone action, are largely un- 
known. This  in  part  is  due  to  the lack of an  insulin-responsive 
cell-free system,  as  most  or  all  the  actions f the  hormone  are 
lost upon  cell disintegration (reviewed in Ref. 4). Therefore, 
agents or conditions  that  either mimic or  inhibit  the effects 
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of insulin may be of use  in elucidating  the  mechanism(s) of 
insulin  action. Several  classes of membrane  perturbants  (re- 
viewed in Ref. 5) are known to mimic the  action of insulin by 
directly perturbing the receptor or interfering with events 
proximal to  the  insulin receptor sites.  These  agents may have 
a limited value in  elucidating  the  postbinding  mechanism(s) 
involved in  hormone  action.  In  contrast,  vanadate ions, which 
mimic insulin by specifically modulating  certain cytoplasmic 
events (6-9), may be of more use. Conditions  or  agents  that 
inhibit  the  actions of insulin  are rare. Some examples  include 
those conditions under which cellular ATP concentrations 
are depleted (10-12). In addition, various anti-calmodulin 
drugs are known to directly inhibit insulin action (13, 14). 
Inhibition of insulin  action by calmodulin inhibitors suggests 
that  either calmodulin or a related  Ca2+-dependent regulatory 
protein may participate  in  one of the  events leading to glucose 
entry  and/or metabolism. These  inhibitors, however, do  not 
interfere with the  ability of insulin to  antagonize lipolysis in 
the  same cells (13). 
In a preliminary communication ( X ) ,  we have demon- 
strated  that polymyxin  B sulfate  (PMXB),’ a cyclic decapep- 
tide  antibiotic,  inhibits  the effect of exogenously administered 
insulin in mice. The anti-insulin action of PMXB is long 
lasting (>12 h),  prevents hypoglycemia and  mortality in mice 
challenged  with  a lethal dose of insulin,  and  is  not mimicked 
by many  substances which resemble PMXB  in  character  and 
structure (15). Even  colistin A sulfate (polymyxin E),  which 
differs from PMXB by a  single  conservative amino acid 
substitution  (see Fig. 1 for structure of PMXB  and  colistin), 
is ineffective in  inhibiting  insulin-mediated hypoglycemia 
(15). 
To  the  best of our knowledge, this is the  first  demonstration 
of a peptide  that  can block the  action of insulin  in  the whole 
animal. In the present study, we extend our preliminary 
observation, seen in mice, to rats. We have also elucidated 
the mechanism of the inhibitory action of PMXB. Since 
colistin A  resembles PMXB  in  structure, charge, and hydro- 
phobic character, but lacks its inhibitory capacity, colistin 
was used as a control  substance  in  many of the  experiments 
described below. 
EXPERIMENTAL PROCEDURES 
Materials-Bovine and porcine insulin were purchased from  Sigma. 
D-[U-“C]Glucose (4-7 mCi/mol), 2-~-[G-~H]deoxyglucose (9 Ci/ 
The abbreviations used are: PMXB, polymyxin B; HEPES, 4-(2- 
hydroxyethy1)-1-piperazineethanesulfonic acid; DAB, diaminobutyric 
acid; MOA, 6-methyloctanoic acid Ac-His,-PMXB, a PMXB deriv- 
ative in which 2 residues of N-acetylhistidine were covalently at- 
tached to  the amino groups of the  PMXB moiety; KRB buffer, Krebs- 
Ringer bicarbonate buffer. 
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mmol), and 2-~-[1,2-~H]deoxyglucose (30.2 Ci/mmol) were from New 
England Nuclear. [U-14C]Sucrose (552 mCi/mmol) and ['251]iodine 
(carrier-free) were obtained from Amersham. Polymyxin B sulfate 
was purchased from Sigma and colistin A from Rafa Israel. Collagen- 
ase type I (134 units/mg) was obtained from Worthington. All other 
materials used in this study were  of analytic grade. 
Deriuatization of PMXB-Succinyl,-PMXB and acety15-PMXB 
were prepared by applying a 200 molar excess of either succinic 
anhydride  or acetic anhydride, respectively, to PMXB (20 mg in 1.0 
ml of 1 M NaHC03). Anhydride addition was performed in aliquots 
of 5 mg each, over a period of 1 h at  5 "C. Acetylz-PMXB and 
succinylz-PMXB were prepared by applying a 10 molar excess of 
either acetic anhydride or succinic anhydride under the above-men- 
tioned conditions. All derivatives were purified on a Sephadex G-10 
column (36 cm X 1.5 cm) pre-equilibrated with 0.1 M NaCl. Deriva- 
tives were eluted from the column with the same 0.1 M NaCl solution. 
The number of amino groups modified by anhydride treatment was 
determined by the trinitrobenzenesulfonic acid method (16). The 
derivative, Ac-Hisz-PMXB, was prepared by coupling PMXB  to N-  
acetylhistidine using l-ethyl-3-(3-dimethylaminopropyl)carbodi- 
imide. The reaction mixture (1.0 ml)  contained 20 mM PMXB, 800 
mM N-acetylhistidine, and 40 mM l-ethyl-3-(3-dimethylamino- 
propy1)carbodiimide. The reaction was allowed to occur for 5 h at pH 
7.0-7.5. The derivative was then purified on a Sephadex G-10 column, 
using 0.1 M NaCl as  the elution buffer. An aliquot of the eluate was 
then acid-hydrolyzed, and  its amino acid composition was determined. 
Under these conditions, it was found that 2 mol of acetylhistidine 
were incorporated per mol of PMXB. Iodination of insulin or Ac- 
Hisz-PMXB using [lZ5I]iodine was performed using the chloramine- 
T method (17). 
Measurement of 2-D-Deoxyglucose Uptake-Measurement of 2- 
deoxyglucose uptake in isolated rat soleus muscles was done using 
male albino rats of the Hebrew University strain (approximately 40 
g/rat). Animals were killed by cervical dislocation, and  the soleus 
muscles were quickly removed and placed under an  02:C02 (95:5 v/ 
v) atmosphere  in 10-ml glass vials sealed with rubber stoppers. The 
muscles were then incubated in  a metabolic shaker (40 cycles/min) 
a t  37 "C. Groups of four muscles each were incubated for 5 min in 
KRB buffer, supplemented with 10 mM HEPES  and 10 mM D-glUCOSe 
in the presence or absence of either PMXB (100 pg/ml) or colistin 
(100 pg/ml). The muscles  were further incubated for 15 min at 37  "C 
in the presence of porcine insulin (0.5 pg/ml). Isolated muscles were 
then washed with 20  ml  of KRB buffer, transferred to vials containing 
KRB with bovine serum albumin (0.25% w/v), 0.5 mM S-deoxyglu- 
cose, 30 pCi of [3H]2-deoxyglucose, and 1 pCi of [14C]sucrose, and 
were incubated for an additional 5 min. Hexose uptake was then 
terminated by three rapid washes with 20 ml of ice-cold KRB buffer 
containing 5 p~ cytochalasin B. 
Treated muscles were then frozen in liquid nitrogen and weighed. 
After thawing, individual muscles were dissolved in 1 ml of 1 N NaOH 
at 70-80 "C for 10 min. Heated samples were then cooled and neu- 
tralized with concentrated HC1 and were counted for radioactive 
content.  Net intracellular 2-deoxyglucose uptake was calculated as 
the difference between the distribution of  [3H]2-deoxyglucose and the 
extracellular marker, [U-"C]sucrose. 
Additional Procedures-The following methods and procedures 
were  used  with no modification: preparation of isolated fat cells from 
epididymal fat pads (18), lipogenesis (19), 2-D-deoxyglucose uptake 
in  fat cells (20), lipolysis and  its inhibition by insulin (21), binding of 
insulin to rat adipocytes (22), and thymidine incorporation into 
smooth muscle cells in culture (23). For plasma glucose determina- 
tions, mice were killed by decapitation and the trunk blood was 
collected and centrifuged to obtain plasma. Plasma glucose  was 
determined using a Beckman Glucose Analyzer, 
RESULTS 
Antihypoglycemic  Effects of PMXB in Rats-Similar to its 
action in mice (15), PMXB (see Fig. 1 for structural configu- 
ration) was found to inhibit the hypoglycemic actions of 
exogenously administered insulin in rats (Fig. 2). Complete 
inhibition of insulin action was obtained at  a 12:l molar ratio 
of PMXB  to insulin. This inhibitory effect by PMXB was 
found to be highly specific, as none of the many other anti- 
biotic or positively charged substances tested showed anti- 
insulin activity (not shown). Colistin A, which differs from 
POLYMYXIN e COLISTIN A 
FIG. 1. The peptide structure of polymyxin B and colistin 
A. The arrows indicate the sole amino acid moiety which differen- 
tiates  PMXB from colistin A. 
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FIG. 2. The effect of polymyxin B on insulin-induced hy- 
poglycemia in rats. Male Wistar rats (100 g)  were in@cted subcu- 
taneously with either 100 pg  of insulin or with insulin plus increasing 
doses of PMXB, as indicated. The  rats were killed 60 min later, and 
the plasma glucose levels were then determined. The d m h d  line 
indicates the mean plasma glucose  levels of control rats.  Each group 
consisted of six rats. 
PMXB by one conservative substitution in  the ring structure 
(see Fig. 1 for structural configuration), was also found to  not 
possess anti-insulin activity (Table I). Of the five amino 
groups of PMXB, only two could be modified without a 
significant loss of activity  (Table I). Octapeptin (Des-DABI- 
Des-Thr2-PMXB)  and a  PMXB-derivative  in which the ul- 
timate tail MOA and  the penultimate DAB were removed, 
Des-MOA-Des-DAB,-PMXB, had 100% and 40% of the orig- 
inal antihypoglycemic activity of PMXB (Table I), respec- 
tively. The latter derivative is devoid of the antibacterial 
action of PMXB (24). 
Cellular Mechanism(s) of Polymyxin B Inhibition of Hypo- 
glycemia-In an  attempt  to understand the mechanism(s) of 
the inhibitory action of PMXB on insulin-induced hypogly- 
cemia in both mice and rats, we tested for the following 
possible conditions. Firstly, we examined the possibility of a 
direct  interaction occurring between PMXB  and insulin 
which might lead to inactivation of the hormone. Secondly, 
we examined for any possible impairment of insulin absorp- 
tion into  the blood circulation, and, finally, we looked for a 
direct action of PMXB on insulin responsiveness in target 
tissues. 
Preincubation of insulin with a 100-fold PMXB did not 
result  in any significant reduction in the ability of insulin to 
stimulate lipogenesis (Table 11). Also, PMXB does not  appear 
to form complexes with insulin, as judged by equilibrium 
dialysis measurements  (Table 11), or by the "peak and trough" 
Polymyxin B Inhibits  Insulin-induce 
TABLE I 
Relative activity of polymyxin B and several polymyxin B derivatives 
in inhibiting insulin-induced hyperglycemia 
Both insulin (2.5 pg/mouse) and/or increasing concentrations of 
PMXB  or  its derivatives were administered by subcutaneous injec- 
tions. Plasma glucose levels were then determined 15 min after 
treatment. 




















a The concentration of PMXB which leads to half-maximal inhi- 
bition of insulin-mediated decreased plasma glucose levels was taken 
as 100%. 
'A PMXB derivative containing an average of 2 mol of DAB- 
linked N-acetylhistidine per mol  of PMXB. 
A polymyxin B derivative containing 2 mol  of succinyl moieties 
per mol  of PMXB. 
A polymyxin B derivative containing  2 mol  of acetyl moieties per 
mol  of PMXB. 
'A polymyxin B derivative in which all five amino groups were 
succinylated. 
A polymyxin B derivative in which all five amino groups were 
acetylated. 
A polymyxin B derivative in which the terminal MOA and DAB, 
were  removed. 
' A polymyxin B derivative which does not contain either DAB, or 
Thr,. 
method (not shown). Moreover, PMXB does not appear to 
interfere with insulin binding either to liver membranes or to 
rat adipocytes (Table 11). It seems then  that  PMXB does not 
complex with or  inactivate insulin in any way. 
We  have found that  the  rate of insulin absorption into  the 
blood circulation is the same in the presence of either  PMXB 
or its inactive analog, colistin (Fig. 3). Co-administration of 
either PMXB or colistin with insulin does not appear to 
enhance  either  absorption  or cleavage of the hormone. Within 
30 min of treatment, about 15-20% of the hormone remains 
intact,  as judged by trichloroacetic acid precipitability and 
radioimmunoassay measurements (Table 111). 
Next we tested the effects of PMXB on insulin responsive- 
ness in rat adipocytes. PMXB  treatment does not  interfere 
with isoproterenol-dependent lipolysis in rat adipocytes, nor 
with insulin inhibition thereof (Table IV). On the  other hand, 
PMXB,  but  not colistin A, abolished the action of insulin in 
stimulating 2-deoxyglucose uptake  (Table IV). Basal levels of 
glucose uptake were only slightly affected (not shown). Sup- 
porting  these results, we further  demonstrated that  PMXB 
also inhibits insulin-stimulated lipogenesis (Fig. 4). Basal 
rates of lipogenesis were also affected by PMXB  treatment, 
but to a much lesser extent. Colistin (100 pg/ml) appears to 
have a slight inhibitory effect on insulin-stimulated lipogen- 
esis (about 20% of that of PMXB),  but had a negligible effect 
on basal levels of lipogenesis (Fig. 4). Half-maximal inhibition 
of lipogenesis was obtained at a  PMXB  concentration of 30 
pg/ml in a representative experiment (Fig. 4). 
Inhibition of Insulin-mediated 2-Deoxyglucose Uptake in 
Rat Soleus Muscle-As muscle tissue has a major role in 
absorbing circulating glucose in response to  an insulin chal- 
lenge in the whole animal, it was essential to determine 
whether PMXB blocks this process in this  target tissue. The 
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TABLE I1 
Lack of interaction of polymyxin B with insulin and with insulin 
receptor 




Insulin pretreated with 100- 
0.15 f 0.03 
0.15 f 0.02 




Formation of insulin-PMXB 
Radioactivity inside tube 44,000 & 500 
Radioactivity outside tube 44,800 & 700 
complexes 
Specific binding of 
'"I-insulin 
Interference with 1251-insulin 
binding 
Rat adipocytes 23 f 2 fmol/106 cells 
Rat adipocytes + PMXB (0.8 22 f 2 fmol/106 cells 
Liver membranes 3.0 & 0.4 fmol/20  pg protein 
Liver membranes + PMXB 3.1 f 0.3 fmol/20 pg protein 
mg/ml) 
(0.8 mg/ml) 
Insulin (2 pg) and  PMXB (200 pg)  were incubated in 60 pl of 0.1 
M phosphate buffer for 5 h. The mixture was then diluted to yield 
various concentrations of insulin, ranging between 0.01 and 10 ng/ 
ml, and was tested for its ability to stimulate lipogenesis. Insulin at 
10 ng/ml gave a 5-fold stimulation over basal activity. EDw values 
were derived from the dose-response curves obtained. 
Insulin (1.0  ml  of 0.6 mg/ml insulin in 0.1 M NaHCOa (pH 7.8)) 
was dialyzed for 12 h at room temperature against a 1-ml solution 
containing 2 X lo" M PMXB and [1261]iodo-His2-PMXB (880,000 
cpm) in  the same buffer. Aliquots (in  triplicate) were then taken for 
determining their radioactive content. 
'Binding was performed for 1 h at  22 'C using 1 nM '%I-insulin 
(for fat cells) or  3 nM lZ6I-insulin (for liver membranes) in the presence 
or the absence of 5 p~ unlabeled insulin. Results are expressed as 
femtomoles of ['251]iodoinsulin bound per aliquot of protein or cell 
number. 
I I I 1 1 1 1 1  
5 , 1  IO 20 30 40 50 60 
Time (minutes) 
FIG. 3. Effects of PMXB and colistin on the circulatory 
absorption  of radiolabeled insulin. Bovine insulin (2.5 pglmouse), 
together with ['261]iodoinsulin  (1.3 X lo6 cpm/mouse) were subcuta- 
neously injected together with either PMXB (250 pg/mouse, 0) or 
colistin (250 pg/mouse, 0). At the indicated times, groups of mice 
were killed, and the amount of radioactivity in the plasma was 
determined. 
results, summarized in Table V, indicate that PMXB, at 100 
pg/ml, completely blocks the effect of insulin in  stimulating 
2-deoxyglucose uptake. Basal levels of glucose uptake were 
not affected by PMXB.  In  contrast, colistin, at 100 pg/ml, did 
not have any effect on either basal or insulin-stimulated 
glucose uptake. 
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TABLE 111 
Processing of exogenously  administered  insulin i n  the rat  after  its co- 
administration  together  with  colistin A or P M X B  
Mice  were injected each with 5 pg  of bovine insulin containing 2 X 
lo6 cpm of ['251]iodoinsulin (250,000 cpm/ng), together with 500 pg 
of PMXB or 500 pg of colistin. Mice  were killed after 30 min. The 
trunk blood  was collected and centrifuged to obtain plasma. 
Total insulin: Trichloro- 
intact + degradedb precipitated immuno- 
acetic acid- Intact Radio- 
(after 30 min) , a ~ ~ ~ ~ i ~ i n )  30 min) assay' 
w / m l  % w / m l  
Insulin + colistin 247 15 37.05 22 
Insulin + PMXB 228 16 36.5 19.5 
Determined by trichloroacetic acid precipitability. 
Determined by standard double-antibody radioimmunoassay. 
* Determined by radioactive content of the serum. 
TABLE IV 
Effect of P M X B  and  colistin on  insulin-mediated  actions i n  rat 
adiuocvtes 
Inhibition of lipolysis 
PMXB (100 pg/ml) 
None 
Isoproterenol (0.02 PM) 
Isoproterenol + insulin 





Insulin (17 nM) 
Insulin + colistin 
Insulin + PMXB (100 pg/mU 
(100 rglml) 
Glycerol released Inhibition 
nmol/3 X 10' 
cells/h 
% 
10 f 1 
10 f 0.8 
125 k 7 
30 f 2  83
33 k 2 80 




0.71 f 0.04 
1.84 f 0.1 
1.72 k 0.12 
0.73 -C 0.07 
" A  suspension of adipocytes was incubated with the indicated 
concentrations of colistin or PMXB for 35 min at  37 "C, and with 
insulin for 30 min at the same temperature. 2-~-Deoxyglucose uptake 
was then measured for 10 min at 37 "C. 
-20- 0 20 40 60 80 100 
Polymyxin B or Colistm (pg/ml) 
FIG. 4. Effects of increasing concentrations of polymyxin B 
and colistin on the active and the basal state of lipogenesis. 
Lipogenesis was carried out in the absence (0,O) or the presence (0, 
B) of insulin (100 ng/ml) and increasing concentrations of colistin or 
PMXB. 
TABLE V 
Inhibition of 2-deoxyglwose  uptake  in  rat soleus  muscle  by 
polymyxin B 
Experimental conditions were as described. 
Additions 2-Deoxyglucose incomorated 
fmol/mg/5 rnin 
None 
Polymyxin B (100 pg/ml) 
19.10 f 2.26 (4) 
22.5 & 1.28 (4) 
Insulin (0.5 pg/ml) 32.46 f 2.16 (4) 
Insulin (0.5 pg/ml) + PMXB (100 pg/ml) 20.02 5 1.52 (4) 
Colistin (100 pg/ml) 19.00 f 0.41 (4) 
Insulin (0.5 pg/ml) + colistin (100 pglml) 34.73 k 2.53 (3) 
TABLE VI 
Effect  of  polymyxin B  and  insulin  on DNA synthesis in cultured 
smooth  muscle cells 
Addition" [3H]Thymidine -Fold incomoratedb stimulation 
cprn/7.7 X 10' cells 95 
None 9,200 f 250 100 
Insulin (17 nM) 
PMXB (10 pg/ml) 
33,600 f 2,500  365 rt 27 
15,800 5 530  172 f 6 
Insulin (17 nM) + PMXB 52,800 f 2,000  574 f 22 
(10 pglrnl) 
a Insulin or PMXB were incubated with cells for a total of  24 h to 
which labeled [3H]thymidine was added for the last 16 h of incubation. 
Cells were subcultured and grown in 35-mm plates containing 3 
ml of Dulbecco's  modified Eagle's medium-0.2% fetal bovine serum 
for 3 days before exposure to either insulin or PMXB. 
Actions of PMXB on Insulin-mediated Synthesis of DNA in 
Smooth Muscle Cells-Polymyxin B at 10 pg/ml does not 
inhibit  the  action(s) of insulin in mediating long term biolog- 
ical effects, such as DNA synthesis (shown in a representative 
experiment, Table  VI). In fact, PMXB itself may have some 
promoting effect upon DNA synthesis (about 27% of that 
obtained by insulin).  This  stimulating effect by PMXB  ap- 
pears to be additive to  the effect of insulin. 
DISCUSSION 
Our studies show that  PMXB is able to counteract  insulin- 
induced hypoglycemia in both mice and  rats. From our exper- 
iments, we conclude that  the ring structure of the peptide 
contains the essential domain(s) involved in anti-insulin  ac- 
tion. While the mechanism of the inhibitory action is not 
completely understood, our studies were aimed at testing 
several possible  modes of action. The observation of the lack 
of interaction between PMXB  and insulin (Table 11) implies 
that the observed inhibitory effect is not a result of the 
inability of the hormone to reach its  target tissue and  bind to 
specific receptor sites. The metabolic degradation of insulin, 
when administered with PMXB or the inactive analog, colis- 
tin (Table 111), was identical in either case and suggests that 
the inhibitory peptide does not modify the  rate of absorption 
or endogenous processing of the hormone. The possibility that 
PMXB triggers a mechanism which results in an increase in 
blood  glucose  levels  was also excluded, since PMXB alone did 
not affect blood  glucose  levels at any  point in time following 
its  administration (15). Moreover, PMXB was  fully active in 
adrenalectomized mice and in mice pretreated with 6-hydrox- 
ydopamine,' g~anethidine,~ phentolamine: propranol01,~ or 
* The catecholamine neurotoxin, 6-hydroxydopamine, was applied 
Guanethidine, the catecholamine depletor, was applied intrave- 
' Phentolamine, the a-adrenergic blocker, was applied intraperi- 
Propranolol, the @-adrenergic blocker, was applied intraperito- 
to mice, intravenously at 50 mg/kg, 48 h before testing. 
nously at 10 mg/kg, 24 h before testing. 
toneally a t  10 mg/kg,  30 min before testing. 
neally at 10 mg/kg, 30 min before testing. 
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indomethacin6 (not shown). Thus,  it  is unlikely that  PMXB 
modulation of secondary endogenous substances, such as  ad- 
renal hormones, sympathetic amines, and prostaglandins, is 
part of the inhibitory process. PMXB, however,  was found in 
in vitro studies to specifically block insulin-dependent glucose 
uptake  and  its metabolism in insulin-responsive tissues, such 
as  fat  or muscle. Other activities of insulin, i.e. the inhibition 
of lipolysis in fat cells or DNA synthesis in smooth muscle 
cells,  were also unaffected by the peptide. 
Taking  into consideration our in vivo and in vitro observa- 
tions in both mice and  rats, we propose that  PMXB exerts 
its inhibitory action at a  post-receptor  site which is specific 
to  the activation of glucose uptake,  and  not to other  insulin- 
dependent activities. To our knowledge, PMXB is the only 
compound capable of specifically blocking insulin-induced 
glucose uptake in both in vitro and in vivo systems, and,  as 
such, may  prove to be a useful experimental tool for studying 
the mechanism of action of insulin in normal and pathological 
states. 
The post-receptor site of PMXB action is currently under 
investigation in our laboratory. Kunn et ai. (25-27) have 
previously demonstrated that  PMXB binds to acidic phos- 
pholipids of various mammalian tissues. Initial  attempts  are 
being undertaken to identify an insulin-dependent  post-bind- 
ing event that may be perturbed by PMXB-phospholipid 
interactions. 
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